Group structure
6 companies in 2 countries
Headquarters not stated1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Loading…
6 companies in 2 countries
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine of every company in the group, current ones first.
1–25 of 49
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ALCAFTADINE0.25% · Solution/drops | Alcaftadine | United States | Marketed | 2023 |
| ALLOPURINOL SODIUM500mg base/vial · Injectable | Allopurinol | United States | Marketed | 2004 |
| ANGIOTENSIN ll ACETATE2.5mg base/ml (eq 2.5mg base/ml) · Solution | Angiotensin ii | United States | Marketed | 2025 |
| ARSENIC TRIOXIDE10ml | 1mg/ml | 2mg/ml · Injectable | Arsenic trioxide | United States | Marketed | 2008 |
| AZELASTINE HYDROCHLORIDE0.05% · Solution/drops | Azelastine | United States | Marketed | 2009 |
| CANGRELOR50mg/vial · Powder | Cangrelor | United States | Marketed | 2025 |
| CASPOFUNGIN ACETATE50mg/vial | 70mg/vial · Powder | Caspofungin | United States | Marketed | 2016 |
| DECITABINE50mg/vial · Injectable | Decitabine | United States | Marketed | 2013 |
| DEXMEDETOMIDINE HYDROCHLORIDE1mg base/250ml (eq 4mcg base/ml) | 200mcg base/2ml (eq 100mcg base/ml) | 200mcg base/50ml (eq 4mcg base/ml) | 400mcg base/100ml (eq 4mcg base/ml) | 80mcg base/20ml (eq 4mcg base/ml) · Injectable | Dexmedetomidine | United States | Marketed | 2014 |
| FLUPHENAZINE DECANOATE25mg/ml · Injectable | Fluphenazine | United States | Marketed | 1987 |
| LATANOPROSTENE BUNOD0.024% · Solution/drops | Latanoprostene bunod | United States | Marketed | 2025 |
| LEVOFLOXACIN500mg/20ml (eq 25mg/ml) | 5mg/ml | 750mg/30ml (eq 25mg/ml) · Injectable | Levofloxacin | United States | Marketed | 2005 |
| NETARSUDIL MESYLATE0.02% · Solution | Netarsudil | United States | Marketed | 2024 |
| POSACONAZOLE300mg/16.7ml (18mg/ml) · Solution | Posaconazole | United States | Marketed | 2022 |
| SELENIOUS ACID12mcg selenium/2ml (eq 6mcg selenium/ml) | 600mcg selenium/10ml (eq 60mcg selenium/ml) | 60mcg selenium/ml (eq 60mcg selenium/ml) · Solution | Selenious acid | United States | Marketed | 2019 |
| TEMSIROLIMUS25mg/ml (25mg/ml) · Solution | Temsirolimus | United States | Marketed | 2018 |
| VANCOMYCIN HYDROCHLORIDE1.25GM BASE/VIAL | 1.5GM BASE/VIAL | 1.75GM BASE/VIAL | 100GM BASE | 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 2GM BASE/VIAL | 750MG BASE/VIAL · Powder | Vancomycin | United States | Marketed | 2016 |
| VASOPRESSIN200units/10ml (20units/ml) | 20units/100ml (0.2units/ml) | 20units/ml (20units/ml) · Solution | Vasopressin (argipressin) | United States | Marketed | 2020 |
| VASOPRESSIN IN DEXTROSE 5%20units/100ml (0.2units/ml) | 40units/100ml (0.4units/ml) · Solution | Vasopressin (argipressin) | United States | Marketed | 2024 |
| VORICONAZOLE200mg/vial · Powder | Voriconazole | United States | Marketed | 2012 |
| ZOLEDRONIC4mg base/100ml · Injectable | Zoledronic acid | United States | Marketed | 2018 |
| Azithromycin TBM | Azithromycin | Saudi Arabia | Authorised | |
| Bortezomib BOS | Bortezomib | Saudi Arabia | Authorised | |
| CASPOFUNGIN 50MG VIAL | Caspofungin | Saudi Arabia | Authorised | |
| CASPOFUNGIN 70MG VIAL | Caspofungin | Saudi Arabia | Authorised |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Saudi Arabia | 25 | 25 | 0 | CompaniesAll medicines |
| United States | 24 | 21 | 3 | CompaniesAll medicines |
Also in the registers of Brazil, Colombia, Malaysia, Singapore
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM otros; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM renovacion; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vencidos; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes, dataset i7cb-raxc, rowsUpdatedAt 1792152574, acquired 2026-10-26; original values retained.
Licence: CC BY-SA 4.0
National Pharmaceutical Regulatory Agency and Ministry of Health Malaysia, KKMNOW Approved Pharmaceutical Products, https://data.moh.gov.my/data-catalogue/pharmaceutical_products; CC BY 4.0; original data as of 2026-09-30 23:59; acquired 2026-10-16T22:34:39.948031+00:00; Prognia preserves original records and projects exact MAL IDs and category/role fields. No government endorsement implied.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0), exact MOH dataset dedication
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Report an error or request removalCorrections from the company itself are welcome.
Keep Gland’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callLicence: Singapore Open Data Licence
U.S. Food and Drug Administration, Drugs@FDA API last updated 2026-10-23; full fixed 19-ID query acquired 2026-10-24T09:17:53.209180+00:00. Original facts retained; Prognia exact ID projection and later-reference resolution; no FDA endorsement.
Licence: openFDA factual NDC data, Creative Commons CC0 1.0 Universal / public domain, third-party and source-listing exceptions retained
Well-known pharmaceutical groups, each with all its companies.